ABSTRACT
Importance The influence of total daily and light intensity activity on cancer risk remains unclear, as most existing knowledge is drawn from studies relying on self-reported leisure-time activities of moderate-vigorous intensity.
Objective To investigate associations between total daily activity, including step counts, and activity intensity on incident cancer risk.
Design, Setting, and Participants Prospective analysis of cancer-free UK Biobank participants who wore accelerometers for 7-days (between 2013-2015), followed for cancer incidence through national registries (mean follow-up 5.8 years (SD=1.3)).
Exposures Time-series machine learning models derived daily total activity (average acceleration), behaviour time, step counts, and peak 30-minute cadence from wrist-based accelerometer data.
Main Outcomes and Measures A composite cancer outcome of 13 cancers previously associated with low physical activity (bladder, breast, colon, endometrial, oesophageal adenocarcinoma, gastric cardia, head and neck, kidney, liver, lung, myeloid leukaemia, myeloma, and rectum) based on previous studies of self-reported activity. Cox proportional hazards regression models estimated hazard ratios (HR) and 95% confidence intervals (CI), adjusted for age, sex, ethnicity, smoking, alcohol, education, Townsend Deprivation Index, and reproductive factors. Associations of reducing sedentary time in favour of increased light and moderate-vigorous activity were examined using compositional data analyses.
Results Among 86 556 participants (mean age 62.0 years (SD=7.9) at accelerometer assessment), 2 669 cancers occurred. Higher total physical activity was associated with a lower overall cancer risk (HR1SD=0.85, [95%CI 0.81-0.89]). On average, reallocating one hour/day from sedentary behaviour to moderate-vigorous physical activity was associated with a lower risk (HR=0.92, [0.89-0.95]), as was reallocating one hour/day to light-intensity physical activity (HR=0.94, [0.92-0.96]). Compared to individuals taking 5 000 daily steps, those who took 9 000 steps had an 18% lower risk of physical-activity-related cancer (HR=0.82, [0.74-0.90]). We found no significant association with peak 30-minute cadence after adjusting for total steps.
Conclusion and Relevance Higher total daily physical activity and less sedentary time, in favour of both light and moderate-vigorous intensity activity, were associated with a lower risk of certain cancers. For less active adults, increasing step counts by 4 000 daily steps may be a practical public health intervention for lowering the risk of some cancers.
Question What insights can we gain about the relationships between total daily activity, step counts, and activity intensity on cancer risk using accelerometer data?
Findings In an analysis of 86 556 individuals from the UK Biobank who provided a week of accelerometer-based activity data, higher levels of total physical activity, reducing sedentary time in favour of light or moderate-vigorous intensity activities, and higher daily step counts were associated with a lower risk of certain cancers.
Meaning For less active adults, increasing activity time and accumulating more daily steps may be practical interventions for lowering the risk of some cancers.
Competing Interest Statement
Conflict of Interest Disclosures: Shreves, Moore, Gaitskell, Travis, and Matthews declare no competing interests. Doherty is supported by Novo Nordisk. Doherty accepted consulting fees from the University of Wisconsin (NIH R01 grant) and Harvard University (NIH R01 grant). Doherty received support for presentations at the International Conference on Soft Computing in Data Science 2021, Korean Society of Cardiology 2020, and Oxford International Study Abroad programme 2023. Doherty received support to attend the 2023 CTSU Joint Annual Collaborators' Meeting, London, 2023 Big Model AI for Drug Design workshop, Abu Dhabi, 2023 Festival of Genomics, London, 2022 Industry Symposium on Digital Biomarkers, EMBL-EBI, Cambridge, 2020 ELIXIR Bioinformatics Industry Forum, London, 2020 3rd NYU Biomedical and Biosystems Conference, Abu Dhabi, 2020 Academy of Medical Sciences, UK-Japan Symposium on Data-Driven Health. Doherty is a member of the 2021 Scientific advisory board EU IMI IDEA-FAST. Doherty received a donation from SwissRe to purchase equipment for accelerometer data collection in the China Kadoorie Biobank. Doherty, Walmsley, and Chan have released accelerometer analysis software under an academic use license that could result in commercial entities paying license fees for their use. Role of the Funder/Sponsor: The funders/sponsors had no role in the design of this study, the analysis and interpretation of the results, or drafting of the manuscript.
Funding Statement
Shreves Saint-Maurice Moore and Matthews were supported by the National Institutes of Health Intramural Research Program Shreves is also supported by the National Institutes of Health Oxford Cambridge Scholars Program Walmsley is supported by HDR UK an initiative funded by UK Research and Innovation Department of Health and Social Care (England) and the devolved administrations Papier is supported by Cancer Research UK (grant number C16077/A29186) Chan is supported by Novo Nordisk Doherty and Small are supported by the Wellcome Trust (223100/Z/21/Z) Doherty is also supported by Novo Nordisk Swiss Re and the British Heart Foundation Centre of Research Excellence (grant number RE/18/3/34214) Travis is supported by Cancer Research UK (grant number C8221/A29017) The funders/sponsors had no role in the design of this study or the analysis and interpretation of the results or drafting of the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank particiapnt provided written informed consent. The study was approved by the National Information Governance Board for Health and Social Care and the National Health Service North West Multicentre Research Ethics Committee (06/MRE08/65).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
We do have permission to share the data. However, all bona fide researchers can apply to use the UK Biobank resource for health-related research that is in the public interest (https://www.ukbiobank.ac.uk/register-apply/).
